Stay updated with breaking news from Advm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adverum Biotechnologies (NASDAQ:ADVM – Get Rating) was upgraded by equities research analysts at Truist Financial from a “hold” rating to a “buy” rating in a report released on Thursday, MarketBeat.com reports. The firm currently has a $4.00 price target on the biotechnology company’s stock, up from their prior price target of $3.00. Truist Financial’s price […]
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating) has been given an average recommendation of “Hold” by the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average 1 year price target among […]
Equities research analysts predict that Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating) will post earnings of ($0.38) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Adverum Biotechnologies’ earnings, with the lowest EPS estimate coming in at ($0.39) and the highest estimate coming in at ($0.36). Adverum Biotechnologies […]
Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating) insider Setareh Seyedkazemi bought 20,000 shares of the business’s stock in a transaction on Monday, May 23rd. The shares were purchased at an average cost of $0.84 per share, for a total transaction of $16,800.00. Following the completion of the purchase, the insider now owns 20,600 shares in […]
Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Rating) have received a consensus rating of “Hold” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to […]